Skip to main content
ABT
NYSE Life Sciences

Abbott Q2 Sales Rise 13%, Raises Full-Year EPS Guidance on Diagnostics and Device Strength

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$90
Mkt Cap
$155.492B
52W Low
$81.97
52W High
$137.49
52W Position info
9.8% above low
Off High info
35% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

ABT is trading near its 52-week low of $81.97 (9.8% above the low).

Summary

Abbott reported Q2 2026 sales of $12.6 billion, up 13% reported, with adjusted EPS of $1.31. The company raised its full-year adjusted EPS guidance to $5.45–$5.60 and reaffirmed comparable sales growth of 6.5%–7.5%.


Key Events · Earnings and Guidance · ABT

  • Q2 Sales Up 13% Reported

    Total sales reached $12.6 billion, with 4.8% comparable growth. Diagnostics surged 42.3% reported (2.9% comparable) driven by the Exact Sciences acquisition, while Medical Devices grew 9.0% reported (8.4% comparable).

  • Adjusted EPS Beats, Guidance Raised

    Adjusted diluted EPS of $1.31 exceeded expectations. Full-year adjusted EPS guidance raised to $5.45–$5.60 from $5.38–$5.58, and Q3 adjusted EPS guided to $1.38–$1.46.

  • Pipeline Milestones Achieved

    CE Mark secured for Libre Duo dual glucose-ketone sensor; FDA submission completed for Amulet 360 LAA device; TECTONIC IVL pivotal trial enrollment completed.

  • GAAP EPS Impacted by Acquisition Charges

    GAAP diluted EPS was $0.53, reflecting $1.36 billion in after-tax specified items including intangible amortization, acquisition costs, and a $385 million legal reserve.


Analysis · ABT · Life Sciences

Abbott delivered a strong second quarter with 13% reported sales growth, driven by the Exact Sciences acquisition and solid organic performance in Medical Devices and Established Pharmaceuticals. Adjusted EPS of $1.31 beat expectations, and management raised full-year adjusted EPS guidance to $5.45–$5.60, signaling confidence in accelerating momentum through the second half. The quarter also featured notable pipeline progress, including CE Mark for the Libre Duo glucose-ketone sensor and an FDA submission for the Amulet 360 LAA device. While GAAP earnings were weighed down by acquisition-related charges and legal reserves, the underlying business is performing well, and the raised guidance is a clear positive for investors.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ABT was trading at $90.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $155.5B. The 52-week trading range was $81.97 to $137.49. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ABT - Latest Insights

ABT
Nov 04, 2026, 4:13 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $115.48
Real-time Price: $103.00 info
Change: -$12.48 (-11%) info
Market Cap: $178.39B info
ABT
Oct 21, 2026, 8:53 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $98.21
Real-time Price: $103.00 info
Change: +$4.79 (+5%) info
Market Cap: $178.39B info
ABT
Oct 21, 2026, 7:36 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $99.52
Real-time Price: $103.00 info
Change: +$3.48 (+3%) info
Market Cap: $178.39B info
ABT
Oct 21, 2026, 7:32 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $100.55
Real-time Price: $103.00 info
Change: +$2.45 (+2%) info
Market Cap: $178.39B info
ABT
Oct 21, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $100.52
Real-time Price: $103.00 info
Change: +$2.48 (+2%) info
Market Cap: $178.39B info